

CMC Biopharmaceuticals A/S and Spine Wave, Inc. Announce Manufacturing Agreement for NuCore™ Injectable Nucleus

Copenhagen, Denmark; August 14, 2006, 2006 – CMC Biopharmaceuticals A/S, a Copenhagen based contract manufacturing organization, and Spine Wave, Inc. a developer of advanced materials, techniques, and implant systems for spine surgery based in Shelton, CT announced today that they have entered into a manufacturing agreement for the cGMP production of the recombinant protein component of Spine Wave's NuCore™ Injectable Nucleus. The product will be manufactured at CMC's facility in Copenhagen, Denmark, for commercial in-market supply.

CMC's facility is state-of-the-art and designed and constructed specifically for contract manufacturing services in full cGMP compliance. Purpose-built to operate with a high degree of flexibility, segregation, and traceability, it is capable of handling simultaneous multi-product manufacturing. The facility has received approval from the Danish Medicines Agency on behalf of EMEA for manufacture of Active Pharmaceutical Ingredients from both microbial and mammalian production systems for Clinical Trials and In-Market supply.

Mr. Mads Laustsen, CMC's CEO, remarked on the agreement: "CMC is delighted to have formed this relationship with Spine Wave. This contract continues to validate CMC's expertise in cGMP manufacturing and reinforces CMC's position as a valid manufacturing partner for companies that are based in the United States. In addition, this relationship provides CMC with exposure to the biomedical device segment of the marketplace."

About CMC Biopharmaceuticals A/S

Based in Copenhagen, Denmark, CMC is a contract development and manufacturing organisation with sales offices located in both Europe and the U.S.

CMC specializes in process and analytical development as well as the scale-up and cGMP manufacture of Active Pharmaceutical Ingredients for pre-clinical, clinical trials and in-market production. CMC's competitive strength is centred around the flexibility it can offer customers combined with the extensive experience of its management and key personnel in the field of biopharmaceutical manufacture and development.

About Spine Wave, Inc.

Connecticut-based Spine Wave is focused on developing and marketing clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The Company's product portfolio includes the NuCore™ Injectable Nucleus (developed in conjunction with technology partner Protein Polymer Technologies, Inc (PPTI)), the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several additional products in development. In January 2006, Spine Wave closed a series C financing and raised \$36.5 million, bringing the total funds raised to date to \$90 million. For more information, visit Spine Wave's website at www.spinewave.com.